Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity.
Publication/Presentation Date
6-1-2026
Abstract
Immunotherapy has significantly improved treatment outcomes for cancer patients within the past decade, with breakthrough results using immune checkpoint inhibitors (ICIs), most notably those targeting the PD-1/PD-L1 inhibitory axis. Nevertheless, many patients and tumor types do not respond to current ICIs, and next-generation drugs are urgently needed. Dual Signaling Protein 216 (DSP216) is a new ligand-based immunotherapeutic-a dual HLA-G and CD47 ICI. DSP216 was designed to exclusively bind to cells co-expressing the immune checkpoints CD47 and HLA-G, thereby mitigating ICI activity towards normal cells expressing only CD47 or HLA-G and associated side effects. Computational chemistry was used to optimize DSP216 affinity to HLA-G with the aim to achieve the desired binding mode and DSP216 binding to CD47
Volume
13
Issue
35
First Page
21448
Last Page
21448
ISSN
2198-3844
Published In/Presented At
Jacob, L. J., Tamir, L., Abdeen, M., Tamir, A., Aronin, A., Bloch, I., Kahn, R., Pecker, I., Tykocinski, M., Huls, G., Pereg, Y., Chajut, A., & Bremer, E. (2026). Selective Targeting of Immune Checkpoints HLA-G and CD47 Using Novel Dual Signaling Protein DSP216 Promotes Innate Anticancer Immunity. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(35), e21448. https://doi.org/10.1002/advs.202521448
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
41662489
Department(s)
Administration and Leadership
Document Type
Article